Case Name: Pharmacyclics LLC v. Alvogen
Pine Brook LLC, Civ. No. 19-434-CFC, 2024 WL 1885677 (D. Del.
Apr. 30, 2024) (Connolly, J.)
Drug Product and Patent(s)-in-Suit:
Imbruvica® (ibrutinib); U.S. Patents Nos. 8,008,309 ("the
'309 patent"), 8,754,090 ("the '090
patent"), 9,655,857 ("the '857 patent"), and
9,725,455 ("the '455 patent")
Nature of the Case and Issue(s) Presented:
Alvogen filed an ANDA with FDA seeking approval to market generic
ibrutinib tablets. Pharmacyclics filed suit, alleging patent
infringement of 18 patents. The Alvogen was litigated
alongside a related action involving other defendants seeking
approval for generic versions of Imbruvica capsules (the Capsule
Action). The Capsule Action and the Alvogen action were
not fully consolidated, but parts of the suits were coordinated
with respect to discovery, and the actions were tried together in
October 2020. After the pretrial conference, Pharmacyclics narrowed
its case to nine claims across
